AMSは北大発認定スタートアップ企業です
AMS to Showcase the World’s First Rapid Treatment
System for Nuclear Medicine Biowaste at BIO 2025
BSL-177 can eliminate regulatory bottlenecks, maximizing patient access to therapies.
BOSTON (June 9, 2025) — At BIO 2025 (June 16-19) in Boston, AMS, the Tokyo-based nuclear medicine startup, will showcase BSL-177, the world’s first rapid treatment system for nuclear medicine biowaste. Leveraging decontamination technology currently in use at Fukushima (Japan’s nuclear accident site), BSL-177 can filter out radioisotopes from patients’ urine in a fraction of the time required conventionally. Using the system can help eliminate regulatory bottlenecks for hospitals, allowing them to maximize patient flow for life-saving nuclear therapies while also enhancing staff safety.
Conventional decontamination takes anywhere from weeks to months, as patients’ urine must be kept in tanks until radioisotopes in it naturally decay and become suitable for sewer discharge per environmental regulations — a time-consuming process that restricts the number of patients hospitals can treat at a time. In contrast, BSL-177 can remove and neutralize 99% of radioisotopes from patients’ urine within 8-12 hours.
Following the market release in Japan earlier this month, BSL-177 is now deployed at leading hospitals across the country. AMS is currently exploring opportunities to bring the system to overseas markets, including the U.S., while also developing a home-use model for the U.S.
Conventional decontamination takes anywhere from weeks to months, as patients’ urine must be kept in tanks until radioisotopes in it naturally decay and become suitable for sewer discharge per environmental regulations — a time-consuming process that restricts the number of patients hospitals can treat at a time. In contrast, BSL-177 can remove and neutralize 99% of radioisotopes from patients’ urine within 8-12 hours.
Following the market release in Japan earlier this month, BSL-177 is now deployed at leading hospitals across the country. AMS is currently exploring opportunities to bring the system to overseas markets, including the U.S., while also developing a home-use model for the U.S.
BIO 2025 Exhibit
June 16-19, 2025
Boston Convention & Exhibition Center (Seaport District)
AMS Exhibit Booth: #2265
June 16-19, 2025
Boston Convention & Exhibition Center (Seaport District)
AMS Exhibit Booth: #2265
“BSL-177 is a transformative tool in nuclear medicine delivery, serving as a key piece of the supporting infrastructure. Japanese hospitals that use the system have already cleared patient backlogs and are able to provide critical therapies without delay,” AMS’s President and CEO Yuichiro Sugawara said. “Our team at AMS drew on our deep expertise and experience in nuclear science and engineering to accomplish a seemingly insurmountable challenge: Finding the best way to layer activated carbon and other materials to achieve a 99% filtration rate. We cannot wait to showcase this fruit of our efforts at BIO 2025.”
The BSL-177 system features two filtration columns — through which water containing urine passes — as well as a tube pump, ultraviolet irradiation system, and lead shield plate. The box-shaped equipment with a cart handle and wheels (measuring L63 x D45 x H86cm, or approx. L25” x D18” x H34”) is designed for hospital settings, as some countries, including Japan, require patients to remain hospitalized for the entire duration of therapies. U.S. patients are typically sent home after each injection with the requirement to stay away from others for a period of time. AMS’s home system for the U.S. market aims to support urine decontamination for enhanced safety and environmental protection.
AMS was founded in 2019 to achieve two intersecting goals: Advancing nuclear medicine and promoting Fukushima’s post-nuclear-accident recovery. On May 30, the company announced it secured $1.0M in its Pre-Series A funding round through a third-party allocation of shares, bringing the total fundraising to date to $2.2M. These funds are expected to accelerate AMS’s efforts to expand into new markets and advance innovative solutions in the pipeline.
The BSL-177 system features two filtration columns — through which water containing urine passes — as well as a tube pump, ultraviolet irradiation system, and lead shield plate. The box-shaped equipment with a cart handle and wheels (measuring L63 x D45 x H86cm, or approx. L25” x D18” x H34”) is designed for hospital settings, as some countries, including Japan, require patients to remain hospitalized for the entire duration of therapies. U.S. patients are typically sent home after each injection with the requirement to stay away from others for a period of time. AMS’s home system for the U.S. market aims to support urine decontamination for enhanced safety and environmental protection.
AMS was founded in 2019 to achieve two intersecting goals: Advancing nuclear medicine and promoting Fukushima’s post-nuclear-accident recovery. On May 30, the company announced it secured $1.0M in its Pre-Series A funding round through a third-party allocation of shares, bringing the total fundraising to date to $2.2M. These funds are expected to accelerate AMS’s efforts to expand into new markets and advance innovative solutions in the pipeline.
About AMS :
AMS is a venture-backed nuclear medicine startup redefining patient access to life-saving treatments. Drawing on decontamination technology currently in use at Fukushima (the site of Japan’s nuclear accident), AMS has developed the world's first filtration system for nuclear therapy biowaste. Building on decades of leadership experience in the highly regulated power utility and healthcare sectors, as well as their expertise in nuclear science and medicine, AMS is uniquely positioned to scale its proprietary technology and maximize access to nuclear medicine worldwide. The company is actively exploring market expansion opportunities in the U.S. and Germany through active discussions with key industry stakeholders. For more information, visit: https://www.ams-plan.com/
AMS is a venture-backed nuclear medicine startup redefining patient access to life-saving treatments. Drawing on decontamination technology currently in use at Fukushima (the site of Japan’s nuclear accident), AMS has developed the world's first filtration system for nuclear therapy biowaste. Building on decades of leadership experience in the highly regulated power utility and healthcare sectors, as well as their expertise in nuclear science and medicine, AMS is uniquely positioned to scale its proprietary technology and maximize access to nuclear medicine worldwide. The company is actively exploring market expansion opportunities in the U.S. and Germany through active discussions with key industry stakeholders. For more information, visit: https://www.ams-plan.com/
About BIO 2025 :
The BIO International Convention is the world’s largest event for biotechnology and attracts 20,000 industry leaders from across the globe. For more information, visit: https://convention.bio.org/
The BIO International Convention is the world’s largest event for biotechnology and attracts 20,000 industry leaders from across the globe. For more information, visit: https://convention.bio.org/